SecBot SecBot
PRESS-RELEASE ·Filed Mar 9, 2026

RLMD

Relmada Therapeutics
NEUTRAL
Impact 6/10
Horizondays Processed8mo ago WireGlobeNewswire
Press release · Offering
Actionable Insight • Neutral

Monitor for the filing of the resale registration statement and watch for any insider trading activity or follow-on commentary on clinical development timelines. The influx of cash extends the runway but adds meaningful dilution; assess whether upcoming catalysts justify the expanded share count.

DirectionNeutral
Confidencehigh
Horizondays

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$7.17
T+0 close · Mar 9, 2026 · via day close
Latest settled
−10.46%
T+60 · $6.42
Vs SPY
−22.45%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Mar 9 $7.17entry
  2. T+1 · 8mo ago −7.67%α −7.49% · $6.62
  3. T+5 · 8mo ago −13.81%α −12.45% · $6.18
  4. T+20 · 7mo ago −5.86%α −3.05% · $6.75
  5. T+60 · 6mo ago −10.46%α −22.45% · $6.42
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Relmada Therapeutics announced a $160 million PIPE financing through the sale of common stock and pre-funded warrants, with proceeds intended for R&D and general corporate purposes. The offering includes significant participation from major healthcare investors and is expected to close March 11, 2026, subject to customary conditions.

Key Financial Metrics

Deal Value
$160.0M

Key Facts

  • Relmada raised $160 million in gross proceeds via a PIPE financing.
  • The offering includes 29,474,569 shares of common stock at $4.75 per share and pre-funded warrants for 4,210,527 shares at $4.749 per warrant.
  • Pre-funded warrants have an exercise price of $0.001 per share.
  • Proceeds will fund working capital, R&D advancement, and general corporate purposes.
  • Major institutional investors participated, including RA Capital, OrbiMed, Janus Henderson, and Balyasny.
  • A registration rights agreement requires Relmada to file a resale registration statement with the SEC.
  • Closing expected on or about March 11, 2026, subject to customary conditions.

Financial Impact

$160 million gross proceeds; significant near-term dilution from 33.7 million new shares (approx 14.3% of current shares outstanding assuming 235M prior float)

dilutioncashequity

Risk Factors

  • Significant shareholder dilution from issuance of ~33.7 million new shares and pre-funded warrants.
  • Resale registration could increase near-term selling pressure as investors may flip shares.
  • No guarantee that R&D spending will lead to clinical success or regulatory approval.

Market Snapshot

Exchange
Nasdaq

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3251705

Track record

11 reports on RLMD

Performance horizon

2 of 3 bullish or bearish reports moved the stock their way by T+20. Best: +38.81% at T+60 after the May 13, 2026 report. 2 of 3 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Bearish 5/10 Entry $3.54 Now $3.61 −1.98% settles Dec 15
  2. Nov 16, 2026today 8-K Neutral 3/10 Entry $4.16 Now $3.61 −13.23% settles Dec 15
  3. Nov 12, 20264d ago 8-K Neutral 4/10 Entry $4.21 Now $3.61 −14.25% settles Dec 14
  4. Sep 11, 20269w ago Insider Cluster Bullish 6/10 Entry $4.52 to $3.39 Now $3.61 −20.13% ▼ −25.00% −26.87% vs SPY
  5. May 13, 202626w ago S-3ASR Bearish 6/10 Entry $7.42 to $6.65 Now $3.61 +51.35% ▲ +10.38% +9.52% vs SPY
  6. May 12, 202626w ago 8-K Neutral 4/10 Entry $7.49 to $6.52 Now $3.61 −51.80% ▼ −12.95% −12.34% vs SPY
  7. Apr 17, 202630w ago DEFA14A Neutral 3/10 Entry $7.37 to $6.34 Now $3.61 −51.02% ▼ −13.98% −18.18% vs SPY
  8. Apr 3, 202632w ago S-3 Neutral 3/10 Entry $6.90 to $7.41 Now $3.61 −47.68% ▲ +7.39% −1.59% vs SPY
  9. Mar 19, 202634w ago Press Release Bullish 8/10 Entry $6.07 to $7.37 Now $3.61 −40.53% ▲ +21.42% +12.10% vs SPY
  10. Mar 12, 202635w ago Press Release Neutral 3/10 Entry $6.15 to $7.29 Now $3.61 −41.30% ▲ +18.54% +16.56% vs SPY
Showing 10 of 11

US Market Status

Market Closed · Opens in 6h 39m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Mar 9, 2026